What was the main PTGX analyst rating action on March 18, 2026?

On March 18, 2026, Jefferies and Johnson Rice both maintained **Buy** ratings on Protagonist Therapeutics, Inc. Jefferies also raised its price target to **$121**, while Johnson Rice highlighted Truist’s **$730,000,000** Icotyde royalty model.

Does the Jefferies price target change affect the PTGX analyst rating outlook?

Jefferies’ raise to a **$121** price target strengthens the positive PTGX analyst rating outlook by increasing implied upside. The maintained Buy indicates conviction, but investors should weigh the target against risks and timing of revenue.

How did the market react to these PTGX analyst rating notes?

The market reaction was muted negative intraday, showing **-0.71% (-$0.69)** and **-0.59% (-$0.58)** moves tied to the Jefferies and Johnson Rice items. That suggests the notes confirmed expectations rather than surprising investors.

How should investors use the PTGX analyst rating in their decisions?

Use the PTGX analyst rating as a data point alongside valuation, pipeline milestones, and cash flow timing. Analysts’ maintained Buys and price targets provide context, but investors must match those to their risk tolerance and horizon.

Analyst Ratings

Jefferies, Johnson Rice Maintain Buy on Protagonist Therapeutics (PTGX) Mar 2026

ByDanny Kontos March 19, 2026

Jefferies and Johnson Rice maintained Buy on Protagonist Therapeutics, Inc. (PTGX) on March 18, 2026. The PTGX analyst rating updates include a Jefferies price target raise to $121 and a Johnson Rice note that cites Truist modeling for $730,000,000 peak Icotyde royalties. Both firms kept positive stances, leaving the rating intact while adjusting the firm view. Investors should note the mixed market reaction and the broader coverage context behind these decisions.